BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 34271171)

  • 1. Sustained and controlled delivery of doxorubicin from an in-situ setting biphasic hydroxyapatite carrier for local treatment of a highly proliferative human osteosarcoma.
    Liu Y; Raina DB; Sebastian S; Nagesh H; Isaksson H; Engellau J; Lidgren L; Tägil M
    Acta Biomater; 2021 Sep; 131():555-571. PubMed ID: 34271171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone mineral: A trojan horse for bone cancers. Efficient mitochondria targeted delivery and tumor eradication with nano hydroxyapatite containing doxorubicin.
    Liu Y; Nadeem A; Sebastian S; Olsson MA; Wai SN; Styring E; Engellau J; Isaksson H; Tägil M; Lidgren L; Raina DB
    Mater Today Bio; 2022 Mar; 14():100227. PubMed ID: 35265825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Redox-sensitive and hyaluronic acid functionalized liposomes for cytoplasmic drug delivery to osteosarcoma in animal models.
    Chi Y; Yin X; Sun K; Feng S; Liu J; Chen D; Guo C; Wu Z
    J Control Release; 2017 Sep; 261():113-125. PubMed ID: 28666726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro evaluation of a biomaterial-based anticancer drug delivery system as an alternative to conventional post-surgery bone cancer treatment.
    Bischoff I; Tsaryk R; Chai F; Fürst R; Kirkpatrick CJ; Unger RE
    Mater Sci Eng C Mater Biol Appl; 2018 Dec; 93():115-124. PubMed ID: 30274043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-delivery of doxorubicin and paclitaxel by reduction/pH dual responsive nanocarriers for osteosarcoma therapy.
    Li Y; Hou H; Zhang P; Zhang Z
    Drug Deliv; 2020 Dec; 27(1):1044-1053. PubMed ID: 32633576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts.
    Gazzano E; Buondonno I; Marengo A; Rolando B; Chegaev K; Kopecka J; Saponara S; Sorge M; Hattinger CM; Gasco A; Fruttero R; Brancaccio M; Serra M; Stella B; Fattal E; Arpicco S; Riganti C
    Cancer Lett; 2019 Aug; 456():29-39. PubMed ID: 31047947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combinational delivery of anticancer drugs for osteosarcoma treatment using electrosprayed core shell nanocarriers.
    Prasad SR; Jayakrishnan A; Kumar TSS
    J Mater Sci Mater Med; 2020 May; 31(5):44. PubMed ID: 32367204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In situ Co-Delivery of Doxorubicin and Cisplatin by Injectable Thermosensitive Hydrogels for Enhanced Osteosarcoma Treatment.
    Si M; Xia Y; Cong M; Wang D; Hou Y; Ma H
    Int J Nanomedicine; 2022; 17():1309-1322. PubMed ID: 35345787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mesenchymal Stem Cell Derived Exosomes as Nanodrug Carrier of Doxorubicin for Targeted Osteosarcoma Therapy via SDF1-CXCR4 Axis.
    Wei H; Chen F; Chen J; Lin H; Wang S; Wang Y; Wu C; Lin J; Zhong G
    Int J Nanomedicine; 2022; 17():3483-3495. PubMed ID: 35959282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pioglitazone modulates doxorubicin resistance in a in vivo model of drug resistant osteosarcoma xenograft.
    Natarajan A; Ramachandran B; Gopisetty G; Jayavelu S; Sundersingh S; Rajkumar T
    Naunyn Schmiedebergs Arch Pharmacol; 2021 Feb; 394(2):361-371. PubMed ID: 33015747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization and Evaluation of Bone-Derived Nanoparticles as a Novel pH-Responsive Carrier for Delivery of Doxorubicin into Breast Cancer Cells.
    Haque ST; Islam RA; Gan SH; Chowdhury EH
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32937817
    [No Abstract]   [Full Text] [Related]  

  • 12. Co-nanoencapsulated doxorubicin and Dz13 control osteosarcoma progression in a murine model.
    Tan ML; Friedhuber AM; Dass CR
    J Pharm Pharmacol; 2013 Jan; 65(1):35-43. PubMed ID: 23215686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a bone-targeted pH-sensitive liposomal formulation containing doxorubicin: physicochemical characterization, cytotoxicity, and biodistribution evaluation in a mouse model of bone metastasis.
    Ferreira Ddos S; Faria SD; Lopes SC; Teixeira CS; Malachias A; Magalhães-Paniago R; de Souza Filho JD; Oliveira BL; Guimarães AR; Caravan P; Ferreira LA; Alves RJ; Oliveira MC
    Int J Nanomedicine; 2016; 11():3737-51. PubMed ID: 27563241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Folic acid decorated metal-organic frameworks loaded with doxorubicin for tumor-targeted chemotherapy of osteosarcoma.
    Xu W; Lou Y; Chen W; Kang Y
    Biomed Tech (Berl); 2020 Apr; 65(2):229-236. PubMed ID: 31605575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-delivery of cisplatin and doxorubicin by covalently conjugating with polyamidoamine dendrimer for enhanced synergistic cancer therapy.
    Guo XL; Kang XX; Wang YQ; Zhang XJ; Li CJ; Liu Y; Du LB
    Acta Biomater; 2019 Jan; 84():367-377. PubMed ID: 30528609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyaluronic acid modified pH-sensitive liposomes for targeted intracellular delivery of doxorubicin.
    Paliwal SR; Paliwal R; Agrawal GP; Vyas SP
    J Liposome Res; 2016 Dec; 26(4):276-87. PubMed ID: 26784587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro delivery and controlled release of Doxorubicin for targeting osteosarcoma bone cancer.
    Kamba SA; Ismail M; Hussein-Al-Ali SH; Ibrahim TA; Zakaria ZA
    Molecules; 2013 Aug; 18(9):10580-98. PubMed ID: 23999729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation, characterization and preliminary pharmacokinetic study of pH-sensitive Hydroxyapatite/Zein nano-drug delivery system for doxorubicin hydrochloride.
    Zha L; Wang B; Qian J; Fletcher B; Zhang C; Dong Q; Chen W; Hong L
    J Pharm Pharmacol; 2020 Apr; 72(4):496-506. PubMed ID: 31975457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EphA2 Targeted Doxorubicin-Nanoliposomes for Osteosarcoma Treatment.
    Haghiralsadat F; Amoabediny G; Naderinezhad S; Nazmi K; De Boer JP; Zandieh-Doulabi B; Forouzanfar T; Helder MN
    Pharm Res; 2017 Dec; 34(12):2891-2900. PubMed ID: 29110283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Doxorubicin and CD‑CUR inclusion complex co‑loaded in thermosensitive hydrogel PLGA‑PEG‑PLGA localized administration for osteosarcoma.
    Yang Z; Liu J; Lu Y
    Int J Oncol; 2020 Aug; 57(2):433-444. PubMed ID: 32468050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.